"Hanmi to Fulfill Shareholder Return Promise... Expanding Cash Dividends and Share Cancellations (Comprehensive)"

Shareholder Return Rate Exceeds 20%
Over 76.6 Billion Won in Treasury Shares to Be Cancelled

Hanmi Group announced on March 16 that it will expand cash dividends and implement share cancellations to enhance shareholder value, leveraging record-breaking results last year from its holding company and major affiliates.

This dividend policy faithfully implements the shareholder return policy officially announced at the company’s corporate presentation, “Hanmi Vision Day,” in December of last year. Hanmi Science is planning a total shareholder return ratio of 30%, Hanmi Pharmaceutical 20%, and JVM over 20%.

Seoul Songpa-gu Hanmi Group Headquarters Building. Hanmi Pharm

The planned cash dividend will be put forward as an agenda item at each company’s regular shareholder meeting on March 31 and will be executed following final approval.

The scale of the cash dividend is as follows: Hanmi Science will pay 300 won per common share (dividend yield: 0.79%), Hanmi Pharmaceutical will pay 2,000 won per common share (dividend yield: 0.40%), and JVM will pay 650 won per common share (dividend yield: 2.5%).

Additionally, Hanmi Group disclosed that it will propose at the regular shareholder meetings an agenda to cancel 70% of treasury shares held by Hanmi Science, Hanmi Pharmaceutical, and JVM, with the remaining 30% to be used for employee compensation.

The disposal volumes are 640,409 shares for Hanmi Science, 121,880 shares for Hanmi Pharmaceutical, and 552,903 shares for JVM. The total cancellation amount for the three companies combined is approximately 76.6 billion won.

Hanmi Science will cancel 448,286 shares (0.66%) out of its 640,409 treasury shares and use the remaining 192,123 shares for employee stock compensation. Hanmi Pharmaceutical will cancel 85,316 shares (0.67%) out of 121,880 shares, with the remaining 36,564 shares to be used as compensation resources.

In the case of JVM, the plan covers 552,903 common shares, which is 4.57% of its total issued shares. Of these, 387,032 shares (3.2%)—accounting for 70%—will be canceled, and the remaining 165,871 shares (30%) will be used for employee stock compensation.

Kim Jae-gyo, CEO of Hanmi Science, stated, “We are actively working to enhance corporate value by maximizing opportunities for future business discovery and strategic growth, while also striving to improve shareholder value through both financial and non-financial means. Based on a stable financial structure, we will continue to expand shareholder-friendly policies by maintaining a balance between investment for growth and shareholder returns.”

Meanwhile, Hanmi Group has unveiled its “New Vision,” targeting combined affiliate sales of 5 trillion won by 2030, based on a stable business environment. At “Hanmi Vision Day,” the group announced a growth strategy roadmap centered on four key areas: obesity, anti-aging, digital healthcare, and robotics.

Hanmi Science aims to achieve an operating margin of over 25% by 2030 by expanding high value-added businesses in medical devices and beauty care, as well as driving the growth of group affiliates. Hanmi Pharmaceutical is targeting an operating margin of over 20% through successful license-outs based on global R&D capabilities and the launch of blockbuster new drugs both domestically and internationally. JVM is also aiming for an operating margin of over 20% through expanding overseas sales in North America and Europe, as well as business expansion in the software sector.

This content was produced with the assistance of AI translation services.